Literature DB >> 1707540

Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen.

M J Losman1, H J Hansen, R M Sharkey, D M Goldenberg, M Monestier.   

Abstract

Anti-idiotype antibodies (Ab2) were purified from a cancer patient treated with NP-4, a murine monoclonal antibody to carcinoembryonic antigen (CEA). These Ab2 were specific for NP-4 and inhibited the binding between NP-4 and CEA. BALB/c mice immunized with these human Ab2 produced anti-Ab2 antibodies that were also reactive with the CEA epitope recognized by NP-4. These results indicate that human Ab2 to NP-4 can antigenically mimic the CEA epitope recognized by NP-4.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1707540      PMCID： PMC51459          DOI： 10.1073/pnas.88.8.3421

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  33 in total

1.  Carcinoembryonic antigen: clinical application.

Authors:  V L Go
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

Review 2.  Possible role of anti-idiotypic antibodies in the induction of tumor immunity.

Authors:  R C Kennedy; E M Zhou; R E Lanford; T C Chanh; C A Bona
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

3.  Absence of circulating antibodies to carcinoembryonic antigen in patients with gastrointestinal malignancies.

Authors:  P Lo Gerfo; F P Herter; S J Bennett
Journal:  Int J Cancer       Date:  1972-03-15       Impact factor: 7.396

4.  Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies.

Authors:  A Mittelman; Z J Chen; T Kageshita; H Yang; M Yamada; P Baskind; N Goldberg; C Puccio; T Ahmed; Z Arlin
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

5.  Towards an idiotype vaccine against mammary tumors. Induction of an immune response to breast cancer-associated antigens by anti-idiotypic antibodies.

Authors:  N I Smorodinsky; Y Ghendler; R Bakimer; S Chaitchuk; I Keydar; Y Shoenfeld
Journal:  Eur J Immunol       Date:  1988-11       Impact factor: 5.532

6.  Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies.

Authors:  M Steinitz; S Tamir; J E Frödin; A K Lefvert; H Mellstedt
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

7.  Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?

Authors:  H Koprowski; D Herlyn; M Lubeck; E DeFreitas; H F Sears
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

8.  Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice.

Authors:  G T Nepom; K A Nelson; S L Holbeck; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Antiidiotype antibodies in cancer patients receiving monoclonal antibody to carcinoembryonic antigen.

Authors:  U C Traub; R L DeJager; F J Primus; M Losman; D M Goldenberg
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

10.  Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta).

Authors:  S Raychaudhuri; Y Saeki; J J Chen; H Iribe; H Fuji; H Kohler
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422
View more
  2 in total

1.  Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72.

Authors:  K Irvine; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

Review 2.  Monoclonal antibodies for cancer immunotherapy.

Authors:  Louis M Weiner; Madhav V Dhodapkar; Soldano Ferrone
Journal:  Lancet       Date:  2009-03-21       Impact factor: 79.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.